Home

Stanoveno Privilegium posluchač teva pharmaceuticals news 2018 Prodavač Sofistikovaný Statečnost

Teva down as it reports lower sales and profit for 2018
Teva down as it reports lower sales and profit for 2018

Teva reports massive $11.6 billion loss, predicts weak 2018 - Business -  Haaretz.com
Teva reports massive $11.6 billion loss, predicts weak 2018 - Business - Haaretz.com

Teva Pharmaceutical falls 6% on eve of Q3 earnings show | Seeking Alpha
Teva Pharmaceutical falls 6% on eve of Q3 earnings show | Seeking Alpha

2017 closes with record approvals of generics, novel drugs; 2018 begins  with reprieves for Teva | Radio Compass Blog
2017 closes with record approvals of generics, novel drugs; 2018 begins with reprieves for Teva | Radio Compass Blog

Teva Stock Dives As The Sales Downfall Continues For Its Biggest Product |  Investor's Business Daily
Teva Stock Dives As The Sales Downfall Continues For Its Biggest Product | Investor's Business Daily

Why Teva Pharmaceuticals Stock Has Two A-Products In The Bag (NYSE:TEVA) |  Seeking Alpha
Why Teva Pharmaceuticals Stock Has Two A-Products In The Bag (NYSE:TEVA) | Seeking Alpha

US Congress grills Teva CEO on Copaxone price hikes - Globes
US Congress grills Teva CEO on Copaxone price hikes - Globes

Pharma giant Teva promises to create over 800 jobs in N.J. Are they worth  $40M? - nj.com
Pharma giant Teva promises to create over 800 jobs in N.J. Are they worth $40M? - nj.com

15. Teva Pharmaceutical Industries | FiercePharma
15. Teva Pharmaceutical Industries | FiercePharma

Global Fluconazole Market 2018 - Pfizer, Bayer, Teva
Global Fluconazole Market 2018 - Pfizer, Bayer, Teva

Feds accuse Teva of $300M in kickbacks for MS drug - Drug Discovery and  Development
Feds accuse Teva of $300M in kickbacks for MS drug - Drug Discovery and Development

ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM  (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with  Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine  in Adults | Business
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business

Teva Announces New Brand Positioning and Visual Identity in North America
Teva Announces New Brand Positioning and Visual Identity in North America

What's behind the timed resurgence of lawsuits against Teva? | Ctech
What's behind the timed resurgence of lawsuits against Teva? | Ctech

Teva Pharmaceutical Industries and opioid settlement: What to know
Teva Pharmaceutical Industries and opioid settlement: What to know

Why Teva Pharmaceuticals Stock Has Two A-Products In The Bag (NYSE:TEVA) |  Seeking Alpha
Why Teva Pharmaceuticals Stock Has Two A-Products In The Bag (NYSE:TEVA) | Seeking Alpha

Teva earnings Q2 2018 | AlphaStreet
Teva earnings Q2 2018 | AlphaStreet

Teva Wins Three, Loses Six in Patent Battle Over Migraine Drug | BioSpace
Teva Wins Three, Loses Six in Patent Battle Over Migraine Drug | BioSpace

18. Teva Pharmaceutical Industries | FiercePharma
18. Teva Pharmaceutical Industries | FiercePharma

Teva concludes $703m women's health products deal with CVC Capital -  Pharmaceutical Technology
Teva concludes $703m women's health products deal with CVC Capital - Pharmaceutical Technology

Teva Pharmaceuticals: Israeli drugmaker to cut 14,000 jobs - BBC News
Teva Pharmaceuticals: Israeli drugmaker to cut 14,000 jobs - BBC News

Patients Eagerly Awaited a Generic Drug. Then They Saw the Price. - The New  York Times
Patients Eagerly Awaited a Generic Drug. Then They Saw the Price. - The New York Times

Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked  Bond Tied to Both Climate and Access to Medicine Targets | News Direct
Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets | News Direct

Teva Pharm to lay off a quarter of workforce, suspends dividend | Reuters
Teva Pharm to lay off a quarter of workforce, suspends dividend | Reuters

Teva Selling $3.5 Billion of Junk Bonds to Refinance Debt - Bloomberg
Teva Selling $3.5 Billion of Junk Bonds to Refinance Debt - Bloomberg

Teva chief reports 'strong progress' in restructuring plan | The Times of  Israel
Teva chief reports 'strong progress' in restructuring plan | The Times of Israel